Saroglitazar

Name: Saroglitazar in Primary biliary cholangitis: Effect of Saroglitazar on quality measures
Published: 2026-09-14T15:39:06-04:00

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Effect of Saroglitazar on quality measures

1 evidence topic · 2 sources

Saroglitazar-specific effect on quality measures

No evidence found.

PBC quality-measure consensus

“Follow-Up Protocols: Establishing evidence-based intervals for treatment response assessments and long-term monitoring.” (opens the source at this quote in a new tab)